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A B S T R A C T   
In Germany, the severity of a narcotic offence is determined based on the classification into different categories 
of quantity. Recently, an amendment to the Narcotics Law regarding the “not inconsiderable quantities” was 
introduced. The new limits for methamphetamine are derived from the varying potency of the respective en-
antiomers. Switzerland, however, does not practice this distinction and there is only one limit quantity, without 
considering the isomeric structure. To examine whether this single value is still contemporary, 26 Thai pill 
samples from the years 2000, 2001, 2007, 2009 and 2017 were analyzed by HPLC-MS/MS and GC-MS. 
Both methods resulted in similar stereoisomeric distributions: the pills mainly consist of the more potent S- 
(+)-methamphetamine, some even being enantiopure. Others show enantiomeric mixtures of R-(− )-/S- 
(+)-methamphetamine, but rarely in an equimolar ratio. There even was one sample, where mainly the less 
potent R-(− )-methamphetamine was detected. 
In conclusion, the analyses revealed that the single value for a “not inconsiderable quantity” in Switzerland 
seems outdated. Most of the sized pills showed a much higher concentration of the more potent S-(+)-meth-
amphetamine. The risks related to taking such a pill are much higher and therefore the limit quantity should be 
adapted to the potency of the respective enantiomers.   
1. Introduction 
According to the United Nations Office on Drugs and Crime’s World 
Drug Report 2019, there are 29 million past-year users of amphetamine- 
type stimulants (ATS) in 2017, being the third largest group of users, 
directly after cannabis and opioids. Moreover, it showed that the form of 
ATS used diverges substantially from region to region. Whereas the non- 
medical use of prescription stimulants and methamphetamine predom-
inate in North America, crystalline methamphetamine prevails in East 
and South-East Asia and Oceania (Australia) and amphetamine in 
Western and Central Europe and the Near and Middle East (World Drug 
Report, 2019). 
ATS are structurally and functionally close to endogenous amines 
and act on the central nervous system increasing the concentrations of 
the neurotransmitters dopamine, serotonin, and norepinephrine in the 
brain. This induces enhanced alertness, increased arousal and generates 
behavioral excitement stimulating motivation, movement, pleasure, and 
reward centers (Kuczenski et al., 1995; Melega et al., 1995; Kish, 2008). 
The leading compounds of this class of drugs are amphetamine 
(α-methylphenethylamine) and methamphetamine (N,α-dimethylphe-
nethylamine), with the latter having a higher potency and a longer 
duration of action due to the additional methyl moiety. This component 
makes the molecule more lipophilic and therefore facilitates the passage 
of the blood brain barrier. Both substances possess a chiral center, which 
results in the drugs being present either as single enantiomers or as a 
mixture of both, depending on the product, the source and/or the syn-
thesis route (see Fig. 1) (Mendelson et al., 2006; Maas et al., 2018). The 
latter is subject to the availability of precursors and can vary from region 
to region. The International Narcotics Control Board’s 2018 Annual 
Report on Precursors suggests that the majority of illicit manufacture of 
methamphetamine in Asia and Oceania, in Africa and in some regions in 
Europe still use ephedrine or pseudoephedrine. In North America, 
however, illicit methamphetamine is nowadays mostly manufactured 
using phenylacetone (P-2-P) (INCB, 2018a). For this reason, 
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methamphetamine is most often encountered on the street as an enan-
tiomeric mixture in the United States. In contrast, it can be assumed that 
the majority of illicit methamphetamine in other parts of the world 
mainly consists of the more potent S-(+)-enantiomer, which provides 
greater stimulant effect and is preferred as illegal street drug. In general, 
the S-(+)-enantiomers are two to four times more potent than their 
corresponding R-(− )-enantiomers (Alles, 1939). 
There are several reasons why it may be important to distinguish 
between the two enantiomers. First, from a toxicological point of view, it 
is necessary to be able to discriminate between a legal and an illegal 
uptake of methamphetamine. This, of course, presupposes that there are 
drugs, which are readily available, like e.g. several over-the-counter 
decongestant products in the United States containing the R-(− )-iso-
mer (West et al., 2013). Toxicological analyses can be performed on 
different samples, e.g. blood/plasma (Hess et al., 2019; Newmeyer et al., 
2014; Peters et al., 2003; Rasmussen et al., 2006), urine (Iio et al., 2005; 
Wang et al., 2015a) or oral fluid (Borg et al., 2018). Second, from the 
perspective of national and international health authorities, enantio-
meric profiling can be used to determine drug use and abuse. Often, 
these studies use wastewater-based epidemiology approaches because it 
provides a near-real time profile of substance abuse (Archer et al., 2018; 
Castrignano et al., 2018; Gao et al., 2018; Xu et al., 2017; Goncalves 
et al., 2019). However, these do not take into account that enantiomeric 
ratios may change during metabolism if racemic methamphetamine is 
consumed (Mendelson et al., 2006). Third, from a chemical point of 
view, enantiomeric analysis can be employed for profiling of metham-
phetamine seizures by inferring the synthetic pathways and providing 
information concerning its precursors. Different analytical methods are 
currently in use for the separation of the two enantiomers: classical 
approaches like capillary electrophoresis (Cui et al., 2018; Liau et al., 
2003), GC-MS with derivatization (Lee et al., 2007; Tsujikawa et al., 
2013) and LC-MS/MS (Wang et al., 2015b) or sophisticated methods like 
the use of molecularly imprinted resin (Alatawi et al., 2018). Currently, 
no systematic analysis of the enatiomeric ratios of so-called “Thai pills”, 
tablets containing methamphetamine and mostly imported from 
Thailand, or crystal meth is carried out in Switzerland. Furthermore, 
there is only very little recent data on enantiomeric ratios of confiscated 
methamphetamine in other European or overseas countries available in 
literature. 
Besides, there is the legal perspective, which of course is closely 
linked to all other three purposes, but above all to forensic toxicology 
and chemistry. In Germany, the severity of a narcotic offence and the 
associated penalty are determined on the basis of the classification into 
different categories of quantity. There recently has been an amendment 
to the Annexes of the Narcotics Law regarding the “not inconsiderable 
quantities”. Based on pharmacological and toxicological findings, the 
following limit quantities for methamphetamine were set: 10 g for the 
enantiomeric mixture of R-(− )/S-(+)-methamphetamine, 5 g for the 
more potent S-(+)-enantiomer and 50 g for the R-(− )-enantiomer. Swiss 
legislation proceeds in a similar way, but defines a “serious” or a 
“qualified” offence. However, no distinction is made between enantio-
pure methamphetamine and an enantiomeric mixture, there is only one 
limit quantity of 12 g, without any specifications regarding the isomeric 
structure and therefore the potency. To examine, whether this single 
value is still contemporary, we have analyzed 26 Thai pill samples from 
different seizures in the Canton of Bern and surrounding Cantons in 
Switzerland from the years 2000, 2001, 2007, 2009 and 2017 with two 
different methods: HPLC-MS/MS and GC-MS with derivatization. 
2. Material and methods 
2.1. Chemicals and reagents 
Cerilliant (Round Rock, TX, USA) provided the enantiopure 
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Fig. 1. Precursors and routes of synthesis for S-(+)-methamphetamine and racemic methamphetamine (according to Mendelson et al., 2006).  
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reference standards R-(− )- & S-(+)-methamphetamine, the racemic 
reference standard (±)-methamphetamine and its deuterated internal 
standard (±)-methamphetamine-d5. The derivatization agent (R)- 
(− )-α-Methoxy-α-(trifluoromethyl)phenylacetyl chloride (R- 
(− )-MPTCl) and ammonium bicarbonate (NH4HCO3) were purchased 
from Sigma-Aldrich (Buchs, Switzerland). Merck (Darmstadt, Germany) 
provided acetonitrile (MeCN, HPLC gradient grade, 99.9%)), ammo-
nium hydroxide solution (NH4OH, 25%), ethanol (EtOH), ethyl acetate 
(EtOAc) and potassium hydroxide (KOH). Biosolve B.V. (Valkenswaard, 
Netherlands) supplied methanol (MeOH, absolute, HPLC grade) and 
ultrapure water type 1 was prepared in-house with a Direct-Q water 
purification system from Millipore (Zug, Switzerland). 
2.2. Thai pills 
Thai pills from a total of 11 seizures from the years 2000–2017 were 
examined. For investigative reasons, some of these seizures have already 
been split into different samples (e.g. seizure 17–02). Where necessary, 
these samples were divided again into different subsets because of 
colour differences of the pills (e.g. sample 07–01.1). Sampling of the 
different samples was conducted in accordance with internal quality 
system procedure (see Table 1) (Steiger et al., 2009). The sampled pills 
were then ground to powder by mortar and pistil. The composition of the 
Thai pills was determined by HPLC-DAD: On average, one Thai pill 
weighed 90 mg and contained 21.2% methamphetamine (range from 
16.2 to 31.2%). 
2.3. Sample preparation 
HPLC-MS/MS sample preparation has been adjusted according to 
internal quality system procedures: 1 mg of powdered sample was dis-
solved in 2 mL of MeOH, sonicated for 5 min and centrifuged for 5 min at 
20 ◦C and ~2500 g. From this solution, 100 μL were withdrawn, diluted 
with 900 μL of MeOH and vortexed. For the analysis, 75 μL of the diluted 
solution were taken and 15 μL of ISTD (10 μg/mL) and 1.41 mL of water 
were added. 
Sample preparation for GC-MS with derivatization to obtain di-
astereomers was performed according to Liau et al. (2003) and Ras-
mussen et al. (2006): 10 mg of powdered sample were dissolved in 1 mL 
of 0.2 N KOH and vortexed for 5 min. Then, 100 μL of this solution were 
extracted with 1 mL of EtOAc, vortexed for 5 min and centrifuged for 5 
min at 20 ◦C and ~900 g. 900 μL of the organic phase were withdrawn 
and 25 μL of derivatization agent (50 μL of R-(− )-MTPACl were diluted 
in 1 mL of MeCN) were added (see Fig. 2). The sample was then heated 
for 2 h at 80 ◦C, cooled down to room temperature, and re-heated for 15 
min at 75 ◦C after adding 100 μL of EtOH. Afterwards, the sample was 
evaporated to dryness under a gentle stream of nitrogen, reconstituted in 
900 μL of EtOAc and sonicated for 2 min. For the analysis, 10 μL of the 
reconstituted solution were then again diluted with 190 μL of EtOAc. 
2.4. HPLC-MS/MS instrumentation 
Enantiomeric concentrations of methamphetamine were determined 
according to Phenomenex® Application Note (Phenomenex Chiral 
Amphetamines, 2363). The LC-MS/MS system consisted of an UltiMate 
3000 HPLC system (Dionex, Olten, Switzerland) coupled to a 5500 
QTRAP hybrid triple quadrupole/linear ion trap mass spectrometer with 
a Turbo V ion source (SCIEX, Brugg, Switzerland). Analyst software 
version 1.6.2 (SCIEX, Brugg, Switzerland) was used for data acquisition 
and analysis. 
Chiral separation by LC was performed with a Lux 3 μm AMP column 
(150 × 3.0 mm), obtained from Phenomenex® (Torrance, CA, USA). 
Mobile phase A was 5 mM NH4HCO3 in water adjusted to pH 11 with 
NH4OH and mobile phase B was MeOH. One microliter aliquots were 
injected and the samples were separated running a gradient from 60% B 
to 95% B over 1 min after an isocratic hold for 10 min. The column was 
re-equilibrated after 2 min, resulting in a total runtime of 13.1 min. 
Mass spectrometric data were acquired in positive electrospray 
ionization and multiple reaction monitoring mode, with an ion spray 
voltage of 5500 V and an ion source temperature of 490 ◦C. Measured 
transitions were R-(− )-/S-(+)-methamphetamine, m/z 150.2 → 91.0* 
and m/z 150.2 → 119.1; and R-(− )-/S-(+)-methamphetamine-d5, m/z 
155.1 → 92.0*. The transitions marked with an asterisk were used for 
quantification. 
2.5. GC-MS instrumentation 
The samples were analyzed using an Agilent Technologies (AT, Basel, 
Switzerland) 5973Network GC system combined with an AT 5973inert 
mass selective detector, an AT 7683 Series injector and auto sampler, 
and MSD ChemStation ver. E.02.02.1431. 
GC was performed with an AT HP-5 MS (cross-linked 5%-phenyl- 
methylpolysiloxane) capillary column (30 m × 0.25 mm i.d., 0.25 μm 
film thickness) with 1 μL splitless injection. The temperature program 
for the column oven was as follows: 50 ◦C for 3 min, a linear ramp to 150 
◦C at 5 ◦C/min, then ramped linearly to 275 ◦C at 25 ◦C/min and held at 
275 ◦C for 4 min. The total analysis time was 32 min. Helium carrier gas 
was used at a constant flow rate of 1.0 mL/min. 
Mass spectrometric parameters were as follows: ionization energy, 
70 eV; ion source temperature, 230 ◦C; full-scan, 30–450 amu. 
3. Results & discussion 
A validation of the HPLC-MS/MS method was performed according 
to internal quality system procedures. Linear regression analysis over 
seven different calibrator levels demonstrated good linearity between 
2.5 and 1250 ng/mL for R-(− )- and S-(+)-methamphetamine with cor-
relation coefficients ≥ 0.9994 (1/x weighting). The limit of detection 
(LOD) and the lower limit of quantification (LLOQ) were found to be 1.0 
ng/mL and 2.5 ng/mL, respectively. Accuracy and imprecision of the 
method were evaluated at four quality control levels. Average accuracy 
for R-(− )- and S-(+)-methamphetamine were 91.8% and 94.3%, 
respectively. Average imprecision were 3.70% relative standard devia-
tion (CV) and 2.57% CV for R-(− )- and S-(+)-methamphetamine, 
Table 1 
Determination of the sampling size of Thai pills.  
Number of pills (X) per sample Sampling size 
1 pill Use the 1 pill 
2–400 pills ̅̅̅x
√
+ 1 (round up)  
>400 pills ̅̅̅x
√
(round up)   
NH
CH3
H CH3
H
H
R/S
Cl
O
CF3H3CO
R+ R
N
H
CH3
OCH3
CF3
OCH3H
H
R/S
Fig. 2. Reaction of R-(− )-/S-(+)-methamphetamine with chiral derivatization reagent R-(− )-MTPACl to form diastereoisomers.  
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respectively. The GC-MS method was tested as alternative method and 
only used for comparison. Since the results were comparable with those 
obtained with the validated LC-MS/MS method, no further validation 
was performed for the time being. 
Enantiomeric separation was achieved with both methods. The 
chromatograms show that baseline separation was obtained for the di-
astereomers with GC-MS, while a slight overlap of the two enantiomers 
can be seen with chiral LC-MS/MS (see Figs. 3–5). Nevertheless, the 
concentrations measured with both methods are very similar and com-
parable (see Tables 2 and 3). They indicate that the Thai pills mainly 
consist of S-(+)-methamphetamine, some seizures even being enantio-
pure and only containing the more potent stereoisomer (e.g. sample 01- 
01). Others show enantiomeric mixtures of R-(− )-/S-(+)-methamphet-
amine, but rarely in an equimolar ratio. The concentration of the more 
Fig. 3. GC chromatograms (TIC) of three derivatized methamphetamine (Meth) samples. Red: R-(− )-Meth (17–04.1); Green: S-(+)-Meth (01-01); Blue: racemic Meth 
(17–02.2). TR 28.65 min: R-(− )-Meth deriv.; TR 28.70 min: S-(+)-Meth deriv. (For interpretation of the references to colour in this figure legend, the reader is referred 
to the Web version of this article.) 
Fig. 4. Electron impact mass spectrum of R-(− )-MTPA-(R/S)-Meth with molecular structure and possible fragment pattern obtained by GC-MS (see Fig. 3).  
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potent S-(+)-methamphetamine most often exceeds that of the R- 
(− )-enantiomer (e.g. samples 07–01.1_1–4). However, there are also two 
cases with an equimolar ratio (e.g. samples 17–02.2 & 17–04.6) and 
even one case, where mainly the less potent R-(− )-methamphetamine 
was detected, but only a small amount of the S-(+)-enantiomer (sample 
17–04.1). 
Even within samples originating from one seizure, different ratios for 
R-(− )- and S-(+)-methamphetamine were detected. Samples 17–02.1 to 
− 02.4, for example, resulted all from the same drug bust. Both, pills 
containing pure S-(+)-methamphetamine were found, but also those 
with an enantiomeric mixture. The same applies to samples 17–04.1 to 
− 04.6, where in addition pills containing mainly the less potent R- 
(− )-enantiomer were encountered. This suggests either that the dealers 
have multiple suppliers or that the manufacturers are using different 
routes of synthesis and precursor substances. 
Furthermore, it can be noticed that the seizures of the years 2000 and 
2001 contain pure S-(+)-methamphetamine, indicating that most likely 
ephedrine or pseudoephedrine was used as precursors. Later, only a few 
of such seizures were found, but almost only enantiomeric mixtures, 
suggesting that mainly P-2-P was utilized as precursor. Similar obser-
vations have been made in other studies, e.g. by Lee et al. (2007) in 
Korea, where enantiomeric impurity started to appear from 1997 and 
have since then gradually increased, or by Wang et al. (2015b) in China, 
where this increase was also discovered between the years 2008 and 
2014. These changes in enantiomeric purity, depending on the route of 
synthesis, are a result of the regulation of available precursors. Ephed-
rine and pseudoephedrine, for example, have been controlled substances 
for some time. It is no longer possible to determine the exact time at 
which these two substances were subjected to the narcotic legislation in 
Switzerland. It certainly took place before 2005, but older versions of 
the Ordinance on precursor chemicals, which came into force in 1997, 
are no longer held by the Federal Chancellery [personal communication 
by Swissmedic]. Internationally, these substances have been under 
control for even longer. After the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances in 1988, the 
International Narcotics Control Board (INCB) compiled the so-called 
“Red List”, containing a list of precursors and chemicals frequently 
used in the illicit manufacture of narcotic drugs and psychotropic sub-
stances under international control, figuring ephedrine, norephedrine, 
pseudoephedrine, but also P-2-P and some of its precursors (INCB, 
2018b). Furthermore, the INCB reported, as mentioned in the intro-
duction, that in some regions of Europe the use of ephedrines is pre-
dominant in the illicit manufacture of methamphetamine (INCB, 
2018a). This statement, however, cannot be confirmed by the results of 
Thai pills sized in 2017 and earlier in Switzerland. They show mainly 
enantiomeric mixtures of R-(− )- and S-(+)-methamphetamine, but in 
non-equimolar ratios, which suggests that the intermediate equimolar 
products from synthesis with P-2-P are purified to obtain a more potent 
substance. This optical resolution can, for example, be conducted using 
l- and d-tartaric acid (Grzechnik et al., 2018). 
Considering the change of concentration of methamphetamine in the 
seized Thai pills over the past years, one can see a small decrease in 
potency, while the weight of the pills stayed constant (at about 90 mg). 
Whereas the pills in the years before 2010 contained a mean concen-
tration of 23% of S-(+)-methamphetamine, the pills sized in 2017 only 
contained 16% in average. This concentration is comparable to the one 
published in the narcotic statistics by the Swiss Society of Forensic 
Medicine (SGRM, 2017). The enantiomeric fraction (EF), which is 
calculated as the fraction between the S-(+)-concentration and the total 
methamphetamine concentration, can be an indicator of purity. The 
resulting EFs, which with a few exceptions are between 0.8 and 1.0, are 
comparable with the EFs from another study (Xu et al., 2017). 
Further international comparisons remain difficult because very 
rarely the pills are analyzed directly, but only the concentrations in 
blood and/or urine after the consumption of methamphetamine. How-
ever, this can also help to get a better overview of the situation on the 
illegal market and to get an answer to the legal question. Wastewater 
analyses in different regions of the world show that the methamphet-
amine consumed in Australia, China, South Africa and a big part of 
Europe is mainly the S-(+)-enantiomer, with some exceptions like the 
UK or Norway, where consumption of racemic methamphetamine was 
detected. The EFs in these studies are also comparable to the ones shown 
in Table 2 (Archer et al., 2018; Castrignano et al., 2018; Gao et al., 
2018). However, one needs to be careful when interpreting these data, 
as it is not possible to distinguish whether the residues originate from 
abuse or other sources, e.g. direct disposal or administration of pre-
scription drugs (Xu et al., 2017). Furthermore, the differences of 
metabolisation ratios between enantiopure and racemic 
Fig. 5. LC chromatograms (MRM1) of three methamphetamine samples. Red: R-(− )-Meth (17–04.1); Green: S-(+)-Meth (01-01); Blue: racemic Meth (17–02.2). TR 
7.94 min: R-(− )-Meth; TR 8.64 min: S-(+)-Meth. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of 
this article.) 
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methamphetamine need to be taken into account as well. 
A similar picture emerges when looking at the results of toxicological 
studies. Two recent studies conducted in Germany show that only one 
case in 106 samples contained both enantiomers, suggesting that 
racemic methamphetamine was consumed. In all other samples only the 
S-(+)-enantiomer was detected, indicating the consumption of enan-
tiopure methamphetamine (Maas et al., 2018; Hess et al., 2019). A 
similar result was obtained by a study conducted in China, where only 
14 out of 86 forensic case samples showed presence of both enantiomers 
(Wang et al., 2015a). 
4. Conclusion 
Enantiomeric separation of methamphetamine in Thai pills from the 
years 2000, 2001, 2007, 2009 and 2017 seized in Switzerland revealed 
that the majority of the samples contain a much higher concentration of 
the more potent S-(+)-methamphetamine. Enantiomeric fractions 
ranged between 0.8 and 1.0 (85%), indicating a mainly enantiopure 
product containing the S-(+)-enantiomer, with a few exceptions of 0.5 
(12%), implying a racemic mixture, and even one case of 0.1, pointing 
towards a product containing primarily the less potent R-(− )-metham-
phetamine. Furthermore, literature research about international 
wastewater and toxicological studies also show that methamphetamine 
is mainly consumed in an enantiopure form of the more potent S- 
(+)-methamphetamine. The risk of taking this substance has become 
much higher and therefore the single limit quantity of 12 g for a 
“serious” or “qualified” offence seems to be outdated and should be 
adapted to the potency of the respective enantiomers. 
Limitations 
The authors are aware that the sample size in this study is limited. 
However, this is related to the fact that only cases that had already been 
closed from a legal perspective could be analyzed. Furthermore, only 
cases with a minimum number of Thai pills could be included in the 
study. As a result, for example, there were no cases that met these 
criteria for the whole year of 2018 and until the completion of this study. 
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00–02 nd N/A 393 19.3 1.0 
01–01 nd N/A 868 31.2 1.0 
01–02 nd N/A 784 25.6 1.0 
07–01.1_1 4.20 0.20 628 26.1 1.0 
07–01.1_2 62.0 2.4 618 24.9 0.9 
07–01.1_3 79.3 3.0 534 21.7 0.9 
07–01.1_4 nd N/A 587 25.0 1.0 
07–01.2_1 43.5 2.1 448 21.2 0.9 
07–01.2_2 72.5 2.8 542 21.9 0.9 
07–02 2.71 0.12 589 23.1 1.0 
09–01.1 nd N/A 492 19.1 1.0 
09–01.2 nd N/A 404 18.1 1.0 
17–01 96.9 2.9 471 14.8 0.8 
17–02.1 < LLOQ N/A 601 16.7 1.0 
17–02.2 322 11.8 354 10.5 0.5 
17–02.3 nd N/A 650 19.4 1.0 
17–02.4 < LLOQ N/A 519 16.3 1.0 
17–03 39.6 1.5 375 15.2 0.9 
17–04.1 698 20.3 56.9 1.7 0.1 
17–04.2 238 8.4 252 9.1 0.5 
17–04.3 61.4 2.2 417 15.7 0.9 
17–04.4 102 3.2 437 14.3 0.8 
17–04.5 51.0 2.2 354 15.4 0.9 
17–04.6 330 8.1 301 8.1 0.5  
Table 3 
Concentrations of R-(− )- and S-(+)-methamphetamine in % of Thai pill analyzed 
by GC-MS.  
SAMPLE R-Meth [%] S-Meth [%] 
(YY–N◦_subset) 
00–01_1 N/A 22.2 
00–01_2 N/A 22.4 
00–02 N/A 19.3 
01–01 N/A 31.2 
01–02 N/A 25.6 
07–01.1_1 0.7 25.6 
07–01.1_2 2.5 24.8 
07–01.1_3 3.7 21.0 
07–01.1_4 0.1 24.9 
07–01.2_1 2.1 21.2 
07–01.2_2 2.6 22.1 
07–02 0.3 22.9 
09–01.1 N/A 19.1 
09–01.2 N/A 18.1 
17–01 3.1 14.7 
17–02.1 0.2 16.6 
17–02.2 10.6 11.8 
17–02.3 N/A 19.4 
17–02.4 0.2 17.1 
17–03 1.5 16.1 
17–04.1 20.9 1.1 
17–04.2 8.3 9.2 
17–04.3 2.0 15.8 
17–04.4 2.3 15.3 
17–04.5 1.9 15.7 
17–04.6 8.6 7.6  
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